These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38167824)

  • 21. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
    Li E; Huang X; Zhang G; Liang T
    J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
    Reva BA; Omelchenko T; Nair SS; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks.
    Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L
    Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the spectrum of immune checkpoints in prostate cancer.
    Sena LA; Denmeade SR; Antonarakis ES
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1253-1266. PubMed ID: 34263692
    [No Abstract]   [Full Text] [Related]  

  • 31. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.
    Harber J; Kamata T; Pritchard C; Fennell D
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.